<DOC>
	<DOCNO>NCT00964574</DOCNO>
	<brief_summary>Primary Objective : To evaluate efficacy safety insulin glulisine type I Diabetes Melittus ( DM ) patient Secondary Objective : To evaluate insulin glulisine dose To assess patient satisfaction</brief_summary>
	<brief_title>Test Efficacy Safety Insulin Glulisine Injected Subcutaneously Patients With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Patients type 1 diabetes mellitus need insulin basal+ bolus regimen 6.5 &lt; =HbA1c &lt; = 11 % visit 1 BMI &lt; 35 kg/mÂ² Provision sign date informed consent prior study procedure Ability willingness complete study diary questionnaires Demonstrated ability use selfglucosemonitoring device , selfinject insulin A negative pregnancy test female childbearing potential . Exclusion criterion : Hypersensitivity insulin Glulisine , insulin Glargine one excipients Pregnant woman Active proliferative diabetic retinopathy Impaired hepatic renal function The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>